A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Trial Profile

A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Neratinib (Primary) ; Trastuzumab emtansine
  • Indications Adenocarcinoma; Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Apr 2017 According to a Puma Biotechnology media release, results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2017.
    • 02 Apr 2017 Results published in the Puma Biotechnology media release.
    • 01 Mar 2017 According to a Puma Biotechnology media release, data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top